Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016', provides in depth analysis on Cathepsin S (CTSS or EC 3.4.22.27) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Cathepsin S (CTSS or EC 3.4.22.27) Overview 6
Therapeutics Development 7
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Stage of Development 7
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Therapy Area 8
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Indication 9
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Companies 12
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development 19
Amura Holdings Limited 19
F. Hoffmann-La Roche Ltd. 20
Fusion Antibodies Limited 21
Sanofi 22
Virobay Inc. 23
Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles 24
AM-3840 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AM-3876 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Fsn-0503h - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
RG-7625 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
RO-5461111 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SAR-114137 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
VBY-036 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
VBY-129 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VBY-285 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VBY-50365 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VBY-825 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Projects 36
Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products 37
Cathepsin S (CTSS or EC 3.4.22.27) - Featured News & Press Releases 38
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease 38
Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting 38
May 23, 2013: Virobay Initiates Phase I Trial Of VBY-036 For Treatment Of Neuropathic Pain 39
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 40

Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Amura Holdings Limited, H2 2016 19
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 20
Pipeline by Fusion Antibodies Limited, H2 2016 21
Pipeline by Sanofi, H2 2016 22
Pipeline by Virobay Inc., H2 2016 23
Dormant Projects, H2 2016 36
Discontinued Products, H2 2016 37